Hemlibra Looks to Reach ‘Ultimate Goal’ of Treating All with Hemophilia A and with Choice in Dosing, Genentech Director Says
News
Should regulatory authorities agree with favorable results from Genentech’s ongoing Phase 3 studies of Hemlibra (emicizumab-kxwh), hemophilia A patients may have a treatment they can use regardless of inhibitor status, with ... Read more